158 related articles for article (PubMed ID: 32167249)
1. [Targeted treatment in spondyloarthritis].
Zanisi L; Nissen MJ
Rev Med Suisse; 2020 Mar; 16(685):482-486. PubMed ID: 32167249
[TBL] [Abstract][Full Text] [Related]
2. Therapy for spondyloarthritis: the role of extra-articular manifestations (eye, skin).
Carron P; Van Praet L; Jacques P; Elewaut D; Van den Bosch F
Rheum Dis Clin North Am; 2012 Aug; 38(3):583-600. PubMed ID: 23083757
[TBL] [Abstract][Full Text] [Related]
3. Disease-modifying Antirheumatic Drugs (DMARD) and Combination Therapy of Conventional DMARD in Patients with Spondyloarthritis and Psoriatic Arthritis with Axial Involvement.
Simone D; Nowik M; Gremese E; Ferraccioli GF
J Rheumatol Suppl; 2015 Nov; 93():65-9. PubMed ID: 26523061
[TBL] [Abstract][Full Text] [Related]
4. Peripheral spondyloarthritis: Concept, diagnosis and treatment.
Molto A; Sieper J
Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):357-368. PubMed ID: 31171308
[TBL] [Abstract][Full Text] [Related]
5. Spondyloarthritis: from unifying concepts to improved treatment.
Paramarta JE; Baeten D
Rheumatology (Oxford); 2014 Sep; 53(9):1547-59. PubMed ID: 24369419
[TBL] [Abstract][Full Text] [Related]
6. [Management of spondyloarthritis].
Claudepierre P
Rev Prat; 2018 Sep; 68(7):740-746. PubMed ID: 30869323
[TBL] [Abstract][Full Text] [Related]
7. [The pharmacotherapy of spondyloarthritis].
Curković B
Reumatizam; 2011; 58(2):65-8. PubMed ID: 22232952
[TBL] [Abstract][Full Text] [Related]
8. An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis.
So A; Inman RD
Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):453-471. PubMed ID: 31171315
[TBL] [Abstract][Full Text] [Related]
9. Acute anterior uveitis and other extra-articular manifestations of spondyloarthritis.
Mitulescu TC; Popescu C; Naie A; Predeţeanu D; Popescu V; Alexandrescu C; Voinea LM
J Med Life; 2015; 8(3):319-25. PubMed ID: 26351533
[TBL] [Abstract][Full Text] [Related]
10. Deciding who to treat with biologic disease-modifying antirheumatic drugs in axial spondyloarthritis.
Wendling D; Goupille P
Immunotherapy; 2020 Aug; 12(12):857-860. PubMed ID: 32635788
[No Abstract] [Full Text] [Related]
11. Axial spondyloarthritis: thoughts about nomenclature and treatment targets.
Braun J
Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S132-5. PubMed ID: 23079005
[TBL] [Abstract][Full Text] [Related]
12. Taiwan Rheumatology Association consensus recommendations for the management of axial spondyloarthritis.
Wei JC; Liu CH; Tseng JC; Hsieh LF; Chen CH; Chen HH; Chen HA; Chen YC; Chou CT; Liao HT; Lin YC; Luo SF; Yang DH; Yeo KJ; Tsai WC;
Int J Rheum Dis; 2020 Jan; 23(1):7-23. PubMed ID: 31777200
[TBL] [Abstract][Full Text] [Related]
13. First-time prescriptions of biological disease-modifying antirheumatic drugs in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis 2002-2011: data from the NOR-DMARD register.
Lie E; Fagerli KM; Mikkelsen K; Rødevand E; Lexberg A; Kalstad S; Uhlig T; Kvien TK
Ann Rheum Dis; 2014 Oct; 73(10):1905-6. PubMed ID: 24989896
[No Abstract] [Full Text] [Related]
14. Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis.
Poddubnyy D; Gensler LS
Best Pract Res Clin Rheumatol; 2014 Oct; 28(5):807-18. PubMed ID: 25488786
[TBL] [Abstract][Full Text] [Related]
15. Impact of ACR 2010 fibromyalgia criteria fulfillment on disease activity evaluation in patients with axial spondyloarthritis treated with infliximab.
Dantu A; Michaud J; Bréhier Q; Banse C; Avenel G; Lequerré T; Pouplin S; Vittecoq O; Verdet M
Joint Bone Spine; 2019 Jan; 86(1):113-114. PubMed ID: 29680208
[No Abstract] [Full Text] [Related]
16. [How to optimize the antiTNF alpha therapy in spondylitis?].
Castro Villegas Mdel C; Escudero Contreras A; Miranda García MD; Collantes Estévez E
Reumatol Clin; 2012 Mar; 8 Suppl 1():S26-31. PubMed ID: 22418285
[TBL] [Abstract][Full Text] [Related]
17. Is there a role for sulphasalazine in axial spondyloarthritis in the era of TNF inhibition? Data from the NOR-DMARD longitudinal observational study.
Fagerli KM; van der Heijde D; Heiberg MS; Wierød A; Kalstad S; Rødevand E; Mikkelsen K; Kvien TK; Lie E
Rheumatology (Oxford); 2014 Jun; 53(6):1087-94. PubMed ID: 24501243
[TBL] [Abstract][Full Text] [Related]
18. The use of secukinumab in an HIV-positive patient with axial spondyloarthritis: a case-based review.
Vílchez-Oya F; Orpinell Palacio L; Castillo Vilella M; González Mena A; Salman-Monte TC
Clin Rheumatol; 2021 Dec; 40(12):5111-5114. PubMed ID: 34529181
[TBL] [Abstract][Full Text] [Related]
19. Malignancies in spondyloarthritis with and without concomitant psoriasis, and the effect of disease modifying anti-rheumatic drugs.
Chung HY; Chan SCW; Chui ETF; Yau T; Lau CS
Clin Exp Rheumatol; 2022 May; 40(5):913-920. PubMed ID: 34369368
[TBL] [Abstract][Full Text] [Related]
20. TNFα antagonist therapy in axial spondyloarthritis: Can we do better?
Prati C; Claudepierre P; Goupille P; Pham T; Wendling D
Joint Bone Spine; 2016 May; 83(3):247-9. PubMed ID: 26875066
[No Abstract] [Full Text] [Related]
[Next] [New Search]
